补中益气丸对乙肝病毒相关失代偿期肝硬化患者5年生存率的影响  

Effects of Buzhong Yiqi Pills on Five-year Survival Rate of HBV-related Decompensated Liver Cirrhosis Patients

作　　者：李海军[1] 郭志梅[1] 杨新英[1] 孙殿兴[1] LI Hai-jun;GUO Zhi-mei;YANG Xin-ying;SUN Dian-xing(Bethune International Peace Hospital, Shijiazhuang 050082, China)

机构地区：[1]解放军白求恩国际和平医院,河北石家庄050082

出　　处：《中国中医药信息杂志》2017年第1期28-31,共4页Chinese Journal of Information on Traditional Chinese Medicine

摘　　要：目的观察长期应用补中益气丸对乙肝病毒(HBV)相关的失代偿期肝硬化患者生存率的影响。方法选取2007年1月1日-2010年1月1日确诊的HBV相关的失代偿期肝硬化患者176例,按照患者意愿分为治疗组82例和对照组94例。2组患者均予抗病毒治疗,根据肝功能及并发症等情况予甘草酸制剂保肝,苦黄注射液退黄,螺内酯、呋塞米利尿治疗。治疗组加用补中益气丸,每次1袋,每日2次,4周为1个疗程,每年应用3个疗程,随访5年。观察补中益气丸对HBV相关的失代偿期肝硬化患者肝肾功能、血凝、血常规、并发症及生存率的影响。结果补中益气丸能够明显改善患者肝肾功能、血常规、血凝等指标,与对照组比较差异均有统计学意义(P<0.05,P<0.01)。治疗组与对照组并发症胸腹水(46.34%、88.30%)、上消化道出血(39.02%、69.15%)、感染(31.71%、57.45%)、肝性脑病(23.17%、54.26%)、肝肾综合征(6.10%、18.09%)、慢性肝功能衰竭(9.76%、25.53%)的发生率比较差异均有统计学意义(P<0.05,P<0.01)。治疗组与对照组5年生存率分别为79.27%和64.89%,2组比较差异有统计学意义(χ2=5.353,P=0.021)。结论长期应用补中益气丸能够明显减少HBV相关的失代偿期肝硬化患者的并发症,提高患者的生存率。Objective To explore the effects of Buzhong Yiqi Pills on HBV-related decompensated liver cirrhosis patients. Methods A total of 176 patients of HBV-related decompensated liver cirrhosis were enrolled in the study from January 2007 to January 2010 and were divided into treatment group (82 cases) and control group (94 cases) according to patient's wishes. Patients in both groups were given antiviral therapy. According to the liver function and complications, patients were given glycyrrhizin to protect liver, Kuhuang Injection to treat jaundice, and spironolactone and furosemide for diuretic treatment. Patients in the treatment group received Buzhong Yiqi Pills, one bag for each time, twice a day, four weeks as a treatment session, three sessions each year, with five-year follow-up.Effects of Buzhong Yiqi Pills on the hepatorenal function, blood coagulation, blood routine, complications and survival rate in patients with decompensated liver cirrhosis were observed. Results Buzhong Yiqi Pills could effectively improve the hepatorenal function, blood routine and coagulation disorders of HBV-related decompensated liver cirrhosis patients (P<0.05, P<0.01). The rate of complications with hydrothorax and ascites (46.34% vs.88.30%), upper gastrointestinal hemorrhage (39.02% vs. 69.15%), infection (31.71% vs. 57.45%), hepatic encephalopathy (23.17% vs. 54.26%), hepatorenal syndrome (6.10% vs. 18.09%) and chronic hepatic failure (9.76%vs. 25.53%) in the treatment group and the control group were with statistical significance (P<0.05, P<0.01). The five-year survival rates were significantly higher in the treatment group (79.27%) compared with the control group(64.89%), with statistical significance (χ2=5.353,P=0.021). Conclusion Long term use of Buzhong Yiqi Pills can significantly decrease the complications of HBV-related decompensated cirrhosis and improve survival rate of patients.

关 键 词：补中益气丸 失代偿期 肝硬化 乙肝病毒 生存率 临床研究 

分 类 号：R259.752[医药卫生—中西医结合]